>>NCT00009217
Inclusion Criteria:.
 - Meets DSM-IV criteria for dementia either sex, age 50 - 95 years.
 - Meets NINCDS-ADRDA criteria for probable Alzheimer's disease.
 - Meets Folstein Mini-Mental State Exam score of 5 - 26, inclusive.
 - Intellectual impairment reported for at least six months.
 - Availability of family member who has had direct contact with the patient for an average of at least once every week during the three months prior to study entry.
 - Has current symptoms of psychosis or agitation. Criteria for "psychosis" requires the presence of delusions and/or hallucinations identified by the Columbia University Scale for Psychopathology in Alzheimer's Disease ( CUSPAD ) and a minimum Brief Psychiatric Rating Scale ( BPRS ) psychosis factor score of at least 4 ( moderate severity ) on one of the following two items: These two items comprise the psychosis factor, excluding the item for conceptual disorganization. Agitation is defined as a score of greater than 3 ( present at least 10 days per month ) on one or more of the CERAD Behavioral Rating Scale for Dementia items for agitation, purposeless wandering, verbal aggression or physical aggression.
 - Free of psychotropic medication for at least two weeks prior to study entry or able to tolerate medication washout for this period.
 - Informed consent by patient and family member, as per IRB procedures at New York State Psychiatric Institute.
 Exclusion Criteria:.
 - Acute unstable medical condition, delirium, alcohol or substance abuse or dependence within the past 1 year.
 - Clinical evidence of stroke, other dementias including vascular or Lewy body or frontotemporal dementia, multiple sclerosis, Parkinson's disease, Huntington's disease, tardive dyskinesia.
 - Diagnosis of a psychotic disorder antedating the onset of dementia.
 - Antipsychotic medication usage during 4 weeks prior to study entry.
 - Contraindication to the use of haloperidol.

>>NCT00089882
Inclusion Criteria:.
 - Adult children or siblings of people with Alzheimer's disease.
 Exclusion Criteria:.
 - Adult children or siblings of people with Alzheimer's disease who are unable to visit a study site.
 - Persons with currently untreated depression, anxiety or severe mood disturbances.
 - Persons with cognitive deficits.

>>NCT00076440
Inclusion Criteria:.
 Patients who satisfy all of the inclusion criteria listed below will be eligible for entry into the trial.
 - Patient and responsible caregiver can give their consent by signing the IRB-approved Informed Consent Form; or, when the patient is judged by the Investigator to be unable to give consent, the legally authorized representative gives consent by signing the consent form and the patient gives assent, in accord with local regulations;.
 - Male;.
 - 65 years of age or older;.
 - Diagnosis of probable AD according to the National Institute of Neurological Disorders-Alzheimer's Disease and Related Disorders Association ( NINDS-ADRDA ) criteria and the Investigator ascertains that the condition was present at least 6 months prior to screening;.
 - Taking a drug for the treatment of AD, such as a cholinesterase inhibitor and/or Memantine, which they began taking at least 90 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial; or, they have never taken such a drug or stopped taking it at least 90 days prior to baseline and will likely refrain from taking such treatment throughout the trial;.
 - Taking other drugs or substances that have purported cognition-enhancing properties such as ginkgo biloba or Vitamin E, which they began taking at least 60 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial; or, they have never taken such a drug or stopped taking it at least 90 days prior to baseline and will likely refrain from taking such treatment throughout the trial;.
 - Mini Mental State Examination ( MMSE ) score of 12 to 24 ( inclusive ) at the screening visit;.
 - Brain imaging study ( CT scan, MRI or PET ) performed at the time of their initial diagnosis of AD or after that time and the findings were consistent with a diagnosis of probable AD, or, if a brain imaging study has not been performed, one will be performed during the screening process;.
 - Rosen Modified Hachinski score of 4 or lower at the screening visit, supporting the Investigator's clinical judgment that the patient's dementia is probable AD and not of vascular origin;.
 - Fluent in English or Spanish and completed at least 6 years of education;.
 - Live at home or in a congregate living facility for requirements other than skilled nursing care and have a caregiver who sees the patient at least three times a week for a total of at least 10 hours and can sign the consent form, provide information pertinent to the patient's cognitive status, accompany the patient on clinic visits and participate in the evaluations.
 - Hamilton Depression Scale ( 17 -item version ) ( HamD ) score of 14 or less at the screening visit;.
 - DEXA scan, performed at screening, within normal limits ( i.e., a T-score of greater than - 2.0 ); or, if their DEXA measure was abnormally low ( i.e., a T-score of - 2.0 or lower ), in either a lumbar vertebra or hip, to specifically include a T-score for the femoral neck ), they were receiving treatment for osteoporosis/osteopenia for at least 3 weeks prior to baseline and that treatment is not expected to change during the course of the trial; or, if their DEXA measure was abnormally low and they are not receiving treatment for osteoporosis/osteopenia, they may proceed to baseline after 3 weeks of treatment for osteoporosis/osteopenia provided that all inclusion/exclusion criteria are met, including assessment of the HamD, concomitant medications, ECG and laboratory tests performed within 45 days of baseline show that they are eligible;.
 - Screening laboratory test values do not indicate significant medical conditions that would interfere with their participation in and completion of the study.
 Exclusion criteria:.
 Patients with any of the exclusion criteria listed below will be ineligible for entry into the study.
 - Female;.
 - Younger than 65 years of age;.
 - Significant neurological disease affecting the brain or psychiatric disease other than AD, such as major depression, schizophrenia, epilepsy, Parkinson's disease or stroke;.
 - Current significant systemic illness or symptoms of organ failure;.
 - Screening ECG shows evidence of a serious and/or unstable condition or a recent ( within 6 months ) myocardial infarction as determined by the Investigator;.
 - PSA test result exceeds 4.0 ng/mL;.
 - Receiving testosterone;.
 - Taking a drug for the treatment of AD for less than 90 days prior to baseline; or, in the opinion of the Investigator, they are likely to either require a change in dose or discontinuation of the drug;.
 - Never received cholinesterase inhibitor treatment and the likelihood of their starting such treatment during the study is other than low or they have taken and discontinued cholinesterase inhibitor treatment in the past and the likelihood of their resuming cholinesterase inhibitor treatment during the study is other than low;.
 - Started or changed within 60 days prior to the screening visit the dosage of any drug ( including OTC ) that affects cognitive function, such as neuroleptics, antidepressants, anxiolytics, sedatives, hypnotics, anti-convulsants, centrally acting antihypertensive agents such as clonidine and Aldomet; or other medications that have been shown to have possible effects on cognition such as Vitamin E, nonsteroidal anti-inflammatory drugs and statins or if, in the Investigator's opinion, the dosage of such medication is likely to be changed during the course of this trial. Any changes in the dosage of any of these drugs during the course of the trial and the reason for the change must be fully recorded in the concomitant medication page of the patient's case report form ( CRF ). If a drug that affects cognition ( e.g., a hypnotic or anxiolytic drug ) is given on a PRN basis, such treatment should be interrupted for 12 hours before a visit, if possible;.
 - Taking coumadin or anti-Parkinsonian medications;.
 - Have taken other investigational drugs within 30 days or 5 half-lives prior to randomization, whichever is longer;.
 - Taking other medications known to affect serum gonadotropin ( Gn ) concentrations, such as goserelin or danazol;.
 - A screening HamD score of 15 or higher;.
 - Abuse or dependence on alcohol or other substances satisfies criteria for DSM-IV categories 303.9 or 305;.
 - Donated blood within 30 days of baseline or are likely to do so during the course of the trial;.
 - History of cancer, particularly breast cancer or known or suspected prostate cancer, within the last 5 years, except for basal cell or squamous cell cancer of the skin;.
 - Clinically significant bladder outlet obstruction, in the judgment of the Investigator or designated examining physician;.
 - Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia or are unable to stand or sit upright for at least 30 minutes;.
 - Sleep apnea.

>>NCT00495820
Inclusion Criteria:.
 1. Diagnosis of dementia of the Alzheimer type ( DSM-IV Text Revision ( TR ) criteria ).
 2. Mini-mental state examination ( MMSE )  > 18 but  < 29.
 3. Apathy Evaluation Scale ( AES ) score of more than 40.
 4. Ability to provide informed consent by either the patient or caregiver.
 5. If subjects are being treated with antidepressants, they should be on a stable dose of antidepressants for at least two months prior to the enrollment into the study.
 6. If subjects are being treated with cholinesterase inhibitors and memantine, they should be on stable dose of those medications at least four months prior to the enrollment into the study.
 Exclusion Criteria:.
 1. Patient currently taking methylphenidate or hypersensitivity or prior significant adverse events with methylphenidate.
 2. Patients currently taking Adderall ( amphetamine mixed salts ) or Dexedrine ( dextroamphetamine sulphate ) or any other amphetamine product.
 3. Uncontrolled hypertension ( BP > 140 - 90 ) or tachycardia ( 100 ) at screening visit.
 4. Patients with frontotemporal dementia.
 5. Patients meeting criteria for Major Depressive Disorder on the Mini International Neuropsychiatric Inventory ( MINI ).
 6. Patients with active psychosis as determined by MINI.
 7. Patients currently being treated with antipsychotics.
 8. History of uncontrolled seizure disorder.
 9. History of malignant hypertension, symptomatic cardiovascular disease, cardiomyopathy, known structural cardiac defect or medically unstable arrhythmias.
 10. History of Tourette's syndrome or presence of motor tics.
 11. Patients with glaucoma.
 12. Patients taking monoamine oxidase inhibitors ( MAOIs ).
 13. Patient taking clonidine.

>>NCT01615666
Inclusion Criteria:.
 - 60 years of age or older ( 50 years of age or older for frontotemporal dementia patients ).
 - Normal memory, mild cognitive impairment ( memory loss that does not significantly affect normal daily activities ) or clinical diagnosis of Alzheimer's disease or frontotemporal dementia ( includes primary progressive aphasia ).
 - Right-handed.
 - General good physical health.
 Exclusion Criteria:.
 - History of stroke or neurological disease ( other than Alzheimer's disease or frontotemporal dementia ).
 - Seizures or head injury with loss of consciousness within the last five years.
 - Ferrous ( magnetic ) or electronic implants ( due to the magnet in the MRI scanner ).
 - Claustrophobia.

>>NCT02129348
Inclusion Criteria:.
 1. Age 55 - 95 years.
 2. Diagnosis of possible or probable AD by standard NIA criteria ( McKahnn et al, 1984; McKhann et all, 2011 ).
 3. Folstein MMSE 5 - 26 out of 30.
 4. Neuropsychiatric Inventory ( NPI ) agitation/aggression subscale score > 4. On each subscale ( frequency X severity ), a score higher than 4 represents moderate to severe symptoms.
 5. Female patients need to be post-menopausal.
 6. Availability of informant; patients without an informant will not be recruited. Patients who lack capacity must have a surrogate.
 Exclusion Criteria:.
 1. Medical contraindication to lithium treatment or prior history of intolerability to lithium treatment.
 Contraindications to lithium in this study include: resting tremor causing functional impairment, history of falls in the last month, untreated thyroid disease or any abnormal thyroid function test ( T3, T4 or TSH ), creatinine level greater than 1.5 mg/100ml or a glomerular filtration rate less than 44ml/min/ 1.73m2; blood pressure > 150 - 90 mm Hg; heart rate < 50 bpm; unstable cardiac disease based on history, physical examination and ECG.
 2. Medications, in combination with lithium, known to have adverse renal effects, including therapeutic or higher doses of diuretics, i.e. hydrochlorothiazide greater than 25mg daily or furosemide greater than 10mg daily. Whenever feasible, patients receiving concomitant antidepressants or antipsychotics will be washed off these medications for at least 24 hours before starting lithium. Patients who do not wish to discontinue antipsychotics or antidepressants, typically because of family member/caregiver objection, will be allowed to enter the trial provided there is no contraindication to concomitant lithium use with that specific psychotropic medication. During the trial, patients will be permitted to receive lorazepam as needed up to 2 mg/day for anxiety/insomnia and non-benzodiazepine hypnotics, e.g., zolpidem.
 3. Current clinical diagnosis of schizophrenia, schizoaffective disorder, other psychosis or bipolar 1 disorder ( DSM-IV TR criteria ).
 4. Current or recent ( past 6 months ) alcohol or substance dependence ( DSM-IV TR criteria ).
 5. Current major depression or suicidality as assessed by the study psychiatrist.
 6. Suicidal behavior or dangerous behavior with serious safety risk or risk of physical harm to self or others.
 7. Parkinson's disease, Lewy body disease, multiple sclerosis, CNS infection, Huntington's disease, amyotrophic lateral sclerosis, other major neurological disorder.
 8. Clinical stroke with residual neurological deficits. MRI findings of cerebrovascular disease ( smallinfarcts, lacunes, periventricular disease ) in the absence of clinical stroke with residual neurological deficits will not lead to exclusion.
 9. Acute, severe, unstable medical illness. For cancer, patients with active illness or metastases will be excluded but past history of successfully treated cancer will not lead to exclusion.
 10. QTc interval > 460 ms at the time of baseline EKG is an exclusion criterion for treatment.
